No data to show
XSTO
INIT
Market cap33mUSD
Apr 11, Last price
5.90SEK
1D
-0.34%
1Q
-18.62%
IPO
27.57%
Name
Initiator Pharma A/S
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.15%
Rev. gr., 5y
%
Revenues
0k
Net income
-23k
L-99.94%
CFO
-12m
L-31.55%
Earnings
May 08, 2025
Profile
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 39 | 65 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (39) | (65) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 5 | (5,677) | |||||||
Tax Rate | |||||||||
NOPAT | (44) | 5,612 | |||||||
Net income | (23) -99.94% | (38,455) 82.56% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 16,552 | 12 | 37,484 | ||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | 15,437 | 12,577 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (13,371) | (8,899) | (26,335) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (12,080) | (17,648) | (32,701) | ||||||
CAPEX | |||||||||
Cash from investing activities | (17) | ||||||||
Cash from financing activities | 1,115 | 2,871 | 37,484 | ||||||
FCF | 852 | (2,290) | 5,612 | ||||||
| Balance | |||||||||
Cash | 13,371 | 24,336 | 38,912 | ||||||
Long term investments | |||||||||
Excess cash | 13,371 | 24,336 | 38,912 | ||||||
Stockholders' equity | 14,782 | 11,162 | 34,023 | ||||||
Invested Capital | 1,411 | 15,437 | 12,577 | ||||||
ROIC | 42.02% | ||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 52,419 | 53,226 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (39) | (65) | |||||||
EV/EBITDA | |||||||||
Interest | 2,392 | ||||||||
Interest/NOPBT | |||||||||